- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06343376
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Study Overview
Status
Conditions
- Recurrent Mantle Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Mantle Cell Lymphoma
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Transformed Chronic Lymphocytic Leukemia
Intervention / Treatment
- Procedure: Computed Tomography
- Procedure: Biospecimen Collection
- Drug: Cyclophosphamide
- Procedure: Leukapheresis
- Procedure: Positron Emission Tomography
- Procedure: Echocardiography
- Procedure: Multigated Acquisition Scan
- Drug: Fludarabine Phosphate
- Procedure: Biopsy
- Procedure: Bone Marrow Biopsy
- Procedure: Bone Marrow Aspiration
- Biological: EGFRt/19-28z/IL-12 CAR T-lymphocytes
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the safety, toxicity and maximum tolerated dose (MTD) of EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T cells) in patients with relapsed or refractory CD19+ aggressive hematologic malignancies.
SECONDARY OBJECTIVES:
I. To assess the anti-tumor efficacy of adoptively transferred EGFRt/19-28z/IL-12 T cells.
II. To assess the in vivo persistence of adoptively transferred EGFRt/19-28z/IL-12 T cells.
EXPLORATORY OBJECTIVES:
I. To describe the cellular and cytokine microenvironment following infusion of adoptively transferred EGFRt/19-28z/IL-12 T cells.
II. To characterize endogenous anti-tumor immune responses following infusion of adoptively transferred EGFRt/19-28z/IL-12 T cells.
III. To summarize levels of normal B cells and the incidence of B cell aplasia following infusion of adoptively transferred EGFRt/19-28z/IL-12 T cells.
IV. To determine the proportion of evaluable patients who achieve minimal residual disease (MRD)-negativity in peripheral blood and/or bone marrow.
V. To assess phenotype and in vitro function of end-of-production (EOP) EGFRt/19-28z/IL-12 CAR T cells and phenotype at recovery following CAR T cell administration.
OUTLINE: This is a dose-escalation study of EGFRt/19- 28z/IL-12 CAR T cells. Patients are assigned to 1 of 2 cohorts.
COHORT A: Patients undergo leukapheresis prior to treatment. Patients receive EGFRt/19- 28z/IL-12 CAR T cells intravenously (IV) over 5 to 30 minutes on day 0. Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients also undergo computed tomography (CT) or positron emission tomography (PET) as well as bone marrow biopsy and aspiration and blood sample collection throughout the trial. Additionally, patients undergo a tissue biopsy during screening and on the trial.
COHORT B: Patients undergo leukapheresis prior to treatment and receive lymphodepletion chemotherapy with cyclophosphamide IV over 2 hours and fludarabine IV over 30 minutes on days -5, -4, and -3. Patients then receive EGFRt/19- 28z/IL-12 CAR T cells IV over 5 to 30 minutes on day 0. Patients also undergo ECHO or MUGA during screening. Patients also undergo CT or PET as well as bone marrow biopsy and aspiration and blood sample collection throughout the trial. Additionally, patients undergo a tissue biopsy during screening and on the trial.
After completion of study treatment, patients are followed up weekly for 4 weeks, every 4 weeks until 24 months, every 3 months thereafter for 1 year, then annually for up to 5 years, followed by long-term follow up for up to 15 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
Principal Investigator:
- Francisco J. Hernandez-ILizaliturri
-
Contact:
- Francisco J. Hernandez-ILizaliturri
- Phone Number: 716-845-1642
- Email: Francisco.Hernandez@RoswellPark.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with relapsed refractory B Cell malignancies which commonly express CD-19.
Eligible disease subtypes include the following:
Patients with diffuse large B-cell lymphoma (de novo or diffuse large B-cell lymphoma [DLBCL] transformed from an indolent lymphoma (follicular lymphoma, chronic lymphocytic leukemia) or high grade B-cell Lymphoma (HGBL):
- Relapsed or refractory DLBCL or high-grade B-cell lymphoma (HGBL) following 2 or more prior chemoimmunotherapy regimens containing an anthracycline and CD20-directed therapy following diagnosis of de novo DLBCL/HGBL or DLBCL arising from indolent lymphoma and requiring further treatment.
- Relapse following a single prior chemoimmunotherapy regimen containing an anthracycline and CD20-directed therapy following diagnosis of de novo DLBCL/HGBL or DLBCL arising from indolent lymphoma and considered ineligible for high dose chemotherapy and autologous stem cell rescue as determined by the investigator.
- Patients must have at least one fludeoxyglucose F-18 (FDG)-avid (PET-avid) measurable lesion.
- Biopsy confirmation of relapsed of refractory DLBCL is required.
- Chronic lymphocytic leukemia after 2 lines of therapy including a BTKi (bruton tyrosine kinase inhibitor).
- Mantle cell lymphoma after 2 lines of therapy. Patients must have previously received chemoimmunotherapy and a prior BTK inhibitor.
- Follicular lymphoma after 2 lines of therapy. Patients must have previously received chemoimmunotherapy and immunomodulatory agent.
- For cohort 1A specifically, patients must additionally have received a prior CD19-targeted CAR T-cell therapy or not have an indication for a Food and Drug Administration (FDA)-approved commercial CD19-targeted CAR T-cell therapy.
- For cohorts other than cohort 1A (and if needed, cohort -1), patients with an indication for an FDA approved commercial CD19-targeted CAR T-cell therapy are eligible following an informed consent discussion that reviews the risks and benefits of the FDA-approved commercial CD19-targeted CAR T-cell therapy vs the investigational product.
- Prior CD19-targeted therapies, including CAR T-cell therapy, does not exclude participation; however, CD19 expression by immunohistochemical staining or flow cytometry must be confirmed prior to enrollment for patients who have received such therapies.
- Age ≥ 18 years of age.
- Creatinine Clearance > 30 mL/min (Cockroft-Gault equation).
- Direct bilirubin ≤ 2.0 mg/dL (unless related to disease).
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (unless related to disease).
- Adequate pulmonary function as assessed by ≥ 90% oxygen saturation on room air by pulse oximetry.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Patients of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished.
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Exclusion Criteria:
- Pregnant or lactating patients.
- Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by ECHO or MUGA scan during screening.
- Patients with active graft versus host disease following allogeneic hematopoietic cell transplantation requiring systemic T cell suppressive therapy are ineligible.
- Patients with active autoimmune disease requiring systemic T cell suppressive therapy are ineligible.
Patients with following cardiac conditions will be excluded:
- New York Heart Association (NYHA) stage III or IV congestive heart failure.
- Myocardial infarction ≤ 6 months prior to enrollment.
- Any history of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration.
- Patients with HIV are ineligible.
- Patients with active hepatitis B infection (as manifest by either detectable hepatitis B virus deoxyribonucleic acid [DNA] by polymerase chain reaction [PCR] and/or positivity for hepatitis B surface antigen) are ineligible.
- Patients with active hepatitis C infection (as manifest by detectable hepatitis C virus ribonucleic acid [RNA] by PCR) are ineligible. Patients with detectable antibodies to hepatitis C virus will be screened by PCR for evidence of active infection.
- Patients with uncontrolled systemic fungal, bacterial, viral or other infection are ineligible.
- Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin.
- Patients with history or presence of clinically significant neurological disorders such as epilepsy, generalized seizure disorder, severe brain injuries are ineligible.
- Patients with primary central nervous system (CNS) disease are ineligible.
- Unwilling or unable to follow protocol requirements.
- Any other condition/issue which, in the opinion of the treating physician, would make the patient ineligible for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A (EGFRt/19- 28z/IL-12 CAR T cells)
Patients undergo leukapheresis prior to treatment.
Patients receive EGFRt/19- 28z/IL-12 CAR T cells IV over 5 to 30 minutes on day 0. Patients also undergo ECHO or MUGA during screening.
Patients also undergo CT or PET as well as bone marrow biopsy and aspiration and blood sample collection throughout the trial.
Additionally, patients undergo a tissue biopsy during screening and on the trial.
|
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo leukapheresis
Other Names:
Undergo PET
Other Names:
Undergo ECHO
Other Names:
Undergo MUGA
Other Names:
Undergo tissue biopsy
Other Names:
Undergo bone marrow biopsy and aspiration
Other Names:
Undergo bone marrow biopsy and aspiration
Given IV
|
Experimental: Cohort B (EGFRt/19- 28z/IL-12 CAR T cells, conditioning)
Patients undergo leukapheresis prior to treatment and receive lymphodepletion chemotherapy with cyclophosphamide IV over 2 hours and fludarabine IV over 30 minutes on days -5, -4, and -3.
Patients then receive EGFRt/19- 28z/IL-12 CAR T cells IV over 5 to 30 minutes on day 0. Patients also undergo ECHO or MUGA during screening.
Patients also undergo CT or PET as well as bone marrow biopsy and aspiration and blood sample collection throughout the trial.
Additionally, patients undergo a tissue biopsy during screening and on the trial.
|
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Undergo leukapheresis
Other Names:
Undergo PET
Other Names:
Undergo ECHO
Other Names:
Undergo MUGA
Other Names:
Given IV
Other Names:
Undergo tissue biopsy
Other Names:
Undergo bone marrow biopsy and aspiration
Other Names:
Undergo bone marrow biopsy and aspiration
Given IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 5 years
|
Will be graded on a scale of 1 to 5 as described by the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).
|
Up to 5 years
|
Maximal tolerated dose (MTD) of EGFRt/19-28z/IL-12 chimeric antigen receptor T-cells
Time Frame: Within 30 days from the final infusion of the EGFRt/19-28z/IL-12 T cells
|
Will be defined as the highest dose with an observed incidence of dose limiting toxicities in no more than one out of six patients treated at a particular dose level.
Will be assessed using NCI CTCAE v 5.0.
|
Within 30 days from the final infusion of the EGFRt/19-28z/IL-12 T cells
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Incidence of complete remission (CR)/complete remission with incomplete count recovery (CRi)
Time Frame: Within 3 months of CAR T-cell infusion
|
Within 3 months of CAR T-cell infusion
|
|
Incidence of CR/CRi + partial response (PR) (ORR)
Time Frame: Within 3 months of CAR T-cell infusion
|
Within 3 months of CAR T-cell infusion
|
|
Event free survival
Time Frame: Up to 5 years
|
Will be computed using the Kaplan- Meier method.
|
Up to 5 years
|
Overall survival
Time Frame: Up to 5 years
|
Will be computed using the Kaplan- Meier method.
|
Up to 5 years
|
Modified T-cell persistence
Time Frame: Up to 5 years
|
Will be determined by the presence of detectable CAR T-cells (quantitative polymerase chain reaction or multiparameter flow cytometry).
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francisco J Hernandez-ILizaliturri, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Disease Attributes
- Hematologic Diseases
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Hematologic Neoplasms
- Leukemia
- Recurrence
- Lymphoma, Mantle-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
- Fludarabine phosphate
Other Study ID Numbers
- I-3641523 (Other Identifier: Roswell Park Cancer Institute)
- NCI-2024-01818 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Mantle Cell Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell LymphomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin LymphomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedIbrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma | Refractory Follicular...United States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); GlaxoSmithKline; Millennium Pharmaceuticals,...TerminatedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Xinqiao Hospital of ChongqingXuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...UnknownRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...China
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Negative | Recurrent Anaplastic Large Cell LymphomaUnited States
Clinical Trials on Computed Tomography
-
Virginia Commonwealth UniversityCompleted
-
University of PadovaUniversity Hospital PadovaRecruitingCraniocerebral Trauma | Platelet Aggregation InhibitorsItaly
-
Stanford UniversitySiemens Healthcare QTCompletedMetastatic Renal Cell CancerUnited States
-
University Hospital, AntwerpCompleted
-
M.D. Anderson Cancer CenterGE HealthcareCompletedLung CancerUnited States
-
Xuzhou Central HospitalCompletedLung Cancer | Lung; NodeChina
-
University Hospital, ToulouseCompletedSinonasal PathologiesFrance
-
Virginia Commonwealth UniversityTerminated
-
University Hospital, GhentEAU Young Academic Urologists Urolithiasis and Endourology Working Group; European... and other collaboratorsEnrolling by invitationNephrolithiasis | Urolithiasis | UreterolithiasisBelgium
-
Jonsson Comprehensive Cancer CenterRecruitingProstate Carcinoma | Recurrent Prostate CarcinomaUnited States